Search for
Thyroglobulin - Cancer Marker
Cancer
Report in 4Hrs
At Home
No Fasting Required
Details
Serves as a precursor for thyroid hormone synthesis and is released into the bloodstream
₹649₹1,450
55% OFF
Thyroglobulin - Cancer Marker
- Why is it done?
- Thyroglobulin (Tg) is a protein produced exclusively by thyroid follicular cells and is used as a tumor marker to detect recurrence or metastasis of thyroid cancer, particularly differentiated thyroid cancers (papillary and follicular types)
- Monitor patients following thyroid cancer treatment, including thyroidectomy and radioactive iodine therapy
- Assess effectiveness of thyroid cancer treatment and detect disease recurrence early
- Identify metastatic disease in patients with known thyroid cancer history
- Typically performed 4-6 weeks after thyroidectomy as a baseline measurement, then periodically during follow-up appointments
- Often measured alongside TSH and anti-thyroglobulin antibodies for comprehensive cancer surveillance
- Normal Range
- Normal/Baseline Reference Range: <0.1 ng/mL to <1.0 ng/mL in patients who have undergone total thyroidectomy
- In non-thyroidectomy patients (intact thyroid): 0.5-53 ng/mL (varies by laboratory)
- Units of Measurement: Nanograms per milliliter (ng/mL)
- Interpretation of Results: Negative/Undetectable (<0.1 ng/mL): Favorable outcome; no detectable cancer recurrence or residual thyroid tissue
- Low/Borderline (0.1-1.0 ng/mL): May indicate minimal residual thyroid tissue or possible micrometastases; requires close monitoring
- Elevated (>1.0 ng/mL): Suggests thyroid cancer recurrence or metastatic disease; warrants further investigation
- Interpretation
- Detectable Thyroglobulin After Total Thyroidectomy: Indicates presence of thyroid tissue; may represent recurrent cancer, metastatic disease, or benign residual thyroid remnant
- Rising Thyroglobulin Trend: Progressive increase in sequential measurements suggests active disease progression; more clinically significant than single absolute value
- Stimulated vs. Unstimulated Thyroglobulin: TSH stimulation (via withdrawal of levothyroxine or recombinant TSH injection) increases sensitivity; stimulated levels are typically higher than unstimulated levels
- Factors Affecting Results:
- Anti-thyroglobulin antibodies: May interfere with measurement and produce false-negative results; requires specific testing consideration
- TSH levels: Higher TSH increases thyroglobulin production from residual thyroid tissue; clinically relevant for test interpretation
- Radioactive iodine therapy: Recently received iodine-131 can temporarily elevate thyroglobulin; allow sufficient time between treatment and testing
- Laboratory methodology: Different assays may yield different results; consistency with same laboratory and method recommended for serial monitoring
- Clinical Significance: Serial measurements more valuable than single result; establishing baseline post-thyroidectomy essential for detecting future changes
- Associated Organs
- Primary Organ System: Thyroid Gland - thyroglobulin is exclusively synthesized by thyroid follicular epithelial cells
- Medical Conditions Associated with Abnormal Results:
- Papillary Thyroid Cancer: Most common thyroid malignancy; elevated thyroglobulin indicates recurrent or metastatic disease
- Follicular Thyroid Cancer: Second most common thyroid cancer; thyroglobulin monitoring critical for detecting distant metastases
- Thyroid Cancer Metastases: May spread to lungs, bones, brain, and liver; elevated thyroglobulin suggests systemic disease presence
- Residual Thyroid Tissue: Benign remnants in thyroid bed after incomplete thyroidectomy; produces low thyroglobulin levels
- Graves' Disease and Thyroiditis: Elevated thyroglobulin due to thyroid inflammation; less useful as cancer marker in these conditions
- Potential Complications/Risks Associated with Abnormal Results:
- Cancer recurrence requiring additional treatment (surgery, chemotherapy, or radiation)
- Distant metastatic disease with potential organ involvement and functional compromise
- Need for more aggressive TSH suppression therapy, requiring higher levothyroxine doses with associated cardiac and metabolic effects
- Psychological burden from cancer recurrence diagnosis and ongoing monitoring anxiety
- Follow-up Tests
- Additional Tests Based on Elevated Thyroglobulin Results:
- TSH Level (Thyroid Stimulating Hormone): Assess thyroid hormone supplementation adequacy and determine if TSH stimulation needed for thyroglobulin interpretation
- Anti-thyroglobulin Antibodies: Detect interference with thyroglobulin measurement; if present, interpret results with caution
- Diagnostic Radioactive Iodine Scan (Iodine-131 Scan): Localize residual thyroid tissue or metastatic disease when thyroglobulin is detectable; highest sensitivity when TSH is elevated
- Thyroid Ultrasound: Evaluate thyroid bed and neck lymph nodes for recurrent disease; non-invasive first-line imaging
- CT or MRI of Chest/Abdomen/Pelvis: Assess for distant metastases to lungs, bones, and other organs when thyroglobulin significantly elevated
- PET Scan (Positron Emission Tomography): Identify metabolically active metastatic lesions; useful for high-risk patients with elevated thyroglobulin
- Fine Needle Aspiration (FNA): Biopsy suspicious lymph nodes or masses identified on imaging
- Monitoring Frequency for Ongoing Thyroid Cancer:
- Low-risk patients: Thyroglobulin measured every 6-12 months for first 5 years, then annually if consistently undetectable
- High-risk patients: More frequent monitoring (every 3-6 months) during first 2-3 years post-treatment
- Lifetime surveillance recommended: Thyroid cancer can recur many years after initial treatment
- Related Complementary Tests:
- Free T4 and Free T3 measurements to assess thyroid hormone status and TSH suppression therapy effectiveness
- Calcitonin levels in patients with history of medullary thyroid cancer (more specific tumor marker for MTC)
- Fasting Required?
- Fasting Requirement: No - Fasting is not required for thyroglobulin testing
- Medications to Avoid:
- Levothyroxine (thyroid hormone replacement): For stimulated thyroglobulin testing, levothyroxine is typically withdrawn 4-6 weeks before testing to allow TSH elevation; continue taking as prescribed for unstimulated measurements
- Biotin/Biotin-containing supplements: May interfere with some immunoassay platforms; discontinue at least 72 hours before testing if instructed by physician
- Iodine-containing supplements or contrast agents: May affect iodine metabolism and thyroid function; inform physician of recent iodine exposure
- Other Patient Preparation Requirements:
- For stimulated thyroglobulin (TSH-stimulated): Option 1 - TSH Withdrawal Method: Stop levothyroxine 4-6 weeks prior; TSH rises naturally above 30 mIU/L, enhancing thyroglobulin secretion. Patients experience hypothyroid symptoms (fatigue, weight gain, cold intolerance) during this period.
- Option 2 - Recombinant TSH (rhTSH) Method: Preferred method; continue levothyroxine and receive intramuscular injections of rhTSH over 2-3 days before testing. Patients avoid hypothyroid symptoms.
- Blood sample collection: Single venipuncture into serum separator tube; no special collection requirements; timing typically done in morning (for consistency in serial monitoring)
- Wait at least 72 hours after radioactive iodine therapy: Recent iodine-131 administration can artificially elevate thyroglobulin levels; timing important for accurate interpretation
- Inform laboratory of clinical context: Whether sample is stimulated or unstimulated, TSH level, presence of anti-thyroglobulin antibodies, and recent treatments; helps laboratory provide appropriate interpretation
- Consistency in testing location: Use same laboratory for serial monitoring when possible; different assays and methodologies may produce different results, making trend interpretation difficult
How our test process works!
